Breaking News Instant updates and real-time market news.

EADSY

Airbus

$20.92

0.57 (2.80%)

, GE

General Electric

$29.00

0.06 (0.21%)

06:13
06/19/17
06/19
06:13
06/19/17
06:13

GECAS orders 100 A320neo aircraft

GE Capital Aviation Services, the commercial aircraft leasing and financing arm of General Electric (GE) has signed a firm order for 100 A320neo (EADSY) Family aircraft at the 52nd International Paris Air Show. GECAS has selected CFM's LEAP-X engine for all 100 A320neo Family aircraft. This new order brings the total number of Airbus aircraft ordered by GECAS to almost 600 aircraft. Of these 220 are A320neo Family aircraft. With more than 5,000 orders received from over 90 customers since its launch in 2010, the A320neo Family has captured some 60% share of the market.

EADSY

Airbus

$20.92

0.57 (2.80%)

GE

General Electric

$29.00

0.06 (0.21%)

  • 20

    Jun

  • 22

    Jun

  • 02

    Oct

EADSY Airbus
$20.92

0.57 (2.80%)

01/05/17
MSCO
01/05/17
UPGRADE
MSCO
Overweight
Airbus upgraded to Overweight from Equal Weight at Morgan Stanley
Price target EUR 76.
01/05/17
JPMS
01/05/17
UPGRADE
JPMS
Neutral
Airbus upgraded to Neutral from Underweight at JPMorgan
02/23/17
JPMS
02/23/17
UPGRADE
JPMS
Overweight
Airbus upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst David Perry upgraded Airbus to Overweight and raised his price target for the shares to EUR 88.50 from EUR 68.
03/21/17
BERN
03/21/17
NO CHANGE
BERN
Airbus shares poised to outperform over the long-term, says Bernstein
Bernstein analyst Douglas Harned expects Airbus' earnings and cash flow growth to accelerate significantly in 2018-2019, enabling the stock to outperform. He raised his price target on the name to EUR88 from EUR83.
GE General Electric
$29.00

0.06 (0.21%)

05/25/17
DBAB
05/25/17
NO CHANGE
Target $24
DBAB
Sell
GE officially walked away from 2018 EPS target, says Deutsche Bank
Deutsche Bank analyst John Inch says General Electric CEO Jeff Immelt at a conference yesterday officially walked away from the company's $2.00-plus earnings per share framework for 2018 citing tougher markets. While investors had expected GE to abandon the $2.00-plus target, the company kept $2.00 per share at the high end of its 2018 framework, Inch tells investors in a research note. He believes $2.00 to be unrealistic, even as just a high point in the range. The analyst sees cash flow pressures continuing in 2018 and keeps a Sell rating on GE with a $24 price target.
05/31/17
DBAB
05/31/17
NO CHANGE
Target $24
DBAB
Sell
General Electric setting stage for dividend cut, says Deutsche Bank
Deutsche Bank analyst John Inch believes the stage is being set for General Electric to cut its common dividend. The analyst has a Sell rating on the shares with a $24 price target. Last Wednesday at a conference, GE provided a cash flow walk for the next two years that suggests it is likely to generate insufficient free cash flow to cover its common dividend this year, and barely enough next year, Inch tells investors in a research note. He believes a "reasonable dividend payout" on a future earnings reset could result in a GE dividend cut to 65c-75c. A dividend reduction could be part of an earnings "reset" lower and possibly in conjunction with eventual future leadership change, Inch writes.
06/01/17
FBCO
06/01/17
NO CHANGE
Target $34
FBCO
Outperform
General Electric has reached attractive entry point, says Credit Suisse
Credit Suisse analyst Julian Mitchell thinks the pendulum of investor sentiment regarding General Electric has swung too far in the negative direction, creating an attractive entry point into the stock. GE's organic growth seems underappreciated, argues Mitchell, who notes that its organic sales growth has topped most Electrical Equipment and Multi-Industry peers in recent years and into 2017. Meanwhile, GE's segments have shown "fairly healthy" operating leverage, added Mitchell, who has an Outperform rating and $34 price target on GE shares.
06/13/17
STFL
06/13/17
NO CHANGE
STFL
New General Electric CEO likely pleases investors, says Stifel
Stifel analyst Robert McCarthy says that investors were probably more pleased with GE's new CEO, John Flannery, than they would have been with either of the other two candidates- GE Power CEO Steve Bolze and CFO Jeff Bornstein. Flannery is viewed as more willing to make major changes than Bolze and is seen as not being as tied to the outgoing CEO as Bornstein, according to McCarthy. The analyst reiterates a $33 price target and a Buy rating on the stock.

TODAY'S FREE FLY STORIES

ISBC

Investors Bancorp

$13.41

0.12 (0.90%)

07:49
09/19/17
09/19
07:49
09/19/17
07:49
Conference/Events
Investors Bancorp management to meet with Deutsche Bank »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

TGS

Transportadora de Gas del Sur SA

$17.48

0.07 (0.40%)

07:49
09/19/17
09/19
07:49
09/19/17
07:49
Initiation
Transportadora de Gas del Sur SA initiated  »

Transportadora de Gas del…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAM

Pampa Energia S.A.

$60.93

0.2 (0.33%)

07:48
09/19/17
09/19
07:48
09/19/17
07:48
Initiation
Pampa Energia S.A. initiated  »

Pampa Energia S.A. …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRGS

Progress Software

$37.49

0.18 (0.48%)

07:47
09/19/17
09/19
07:47
09/19/17
07:47
Hot Stocks
Breaking Hot Stocks news story on Progress Software »

Progress:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRGS

Progress Software

$37.49

0.18 (0.48%)

07:47
09/19/17
09/19
07:47
09/19/17
07:47
Hot Stocks
Progress Software 'values' Praesidium's ideas, welcomes input from investors »

In response to a letter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JEC

Jacobs Engineering

$56.76

0.81 (1.45%)

, AERI

Aerie Pharmaceuticals

$60.10

1.8 (3.09%)

07:46
09/19/17
09/19
07:46
09/19/17
07:46
Hot Stocks
Jacobs Engineering selected by Aerie Pharmaceuticals as engineering contractor »

Jacobs Engineering Group…

JEC

Jacobs Engineering

$56.76

0.81 (1.45%)

AERI

Aerie Pharmaceuticals

$60.10

1.8 (3.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

  • 28

    Feb

BNPQY

BNP Paribas

$39.68

0.19 (0.48%)

, AXAHY

AXA

$29.47

0.13 (0.44%)

07:46
09/19/17
09/19
07:46
09/19/17
07:46
Periodicals
BNP weighing tie-up of money-management division with Axa unit, Bloomberg says »

BNP Paribas (BNPQY),…

BNPQY

BNP Paribas

$39.68

0.19 (0.48%)

AXAHY

AXA

$29.47

0.13 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHFC

Chemical Financial

$49.32

0.71 (1.46%)

07:45
09/19/17
09/19
07:45
09/19/17
07:45
Downgrade
Chemical Financial rating change  »

Chemical Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QSII

Quality Systems

$15.71

-0.14 (-0.88%)

07:45
09/19/17
09/19
07:45
09/19/17
07:45
Initiation
Quality Systems initiated  »

Quality Systems initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:45
09/19/17
09/19
07:45
09/19/17
07:45
General news
N.Y. FX Outlook »

N.Y. FX Outlook: Risk-on…

HOLI

Hollysys

$20.77

0.42 (2.06%)

07:44
09/19/17
09/19
07:44
09/19/17
07:44
Conference/Events
Hollysys management to meet with Deutsche Bank »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 16

    Oct

CYTK

Cytokinetics

$14.25

0.1 (0.71%)

, AMGN

Amgen

$186.47

-1 (-0.53%)

07:44
09/19/17
09/19
07:44
09/19/17
07:44
Hot Stocks
Cytokinetics doses first patient in Japan in GALACTIC-HF Phase 3 trial »

Cytokinetics announced…

CYTK

Cytokinetics

$14.25

0.1 (0.71%)

AMGN

Amgen

$186.47

-1 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 02

    Dec

  • 03

    Feb

  • 30

    Apr

  • 17

    May

KORS

Michael Kors

$44.65

-0.27 (-0.60%)

07:43
09/19/17
09/19
07:43
09/19/17
07:43
Technical Analysis
Technical View: Michael Kors moves higher, analyst action »

Shares were last up over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

07:43
09/19/17
09/19
07:43
09/19/17
07:43
Periodicals
Intel Capital invested over $1B in AI-focused companies, TechCrunch says »

Intel has invested more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 05

    Oct

PDCO

Patterson Companies

$37.94

-0.59 (-1.53%)

07:43
09/19/17
09/19
07:43
09/19/17
07:43
Initiation
Patterson Companies initiated  »

Patterson Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$179.98

3.28 (1.86%)

, BSTI

BEST Inc

07:43
09/19/17
09/19
07:43
09/19/17
07:43
Syndicate
BEST Inc cuts size of proposed IPO following 'tepid' response, Reuters reports »

Best Inc (BSTI), a…

BABA

Alibaba

$179.98

3.28 (1.86%)

BSTI

BEST Inc

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

FOLD

Amicus

$13.67

-0.21 (-1.51%)

07:42
09/19/17
09/19
07:42
09/19/17
07:42
Hot Stocks
Amicus granted FDA Fast Track Designation for migalastat »

Amicus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RAD

Rite Aid

$2.73

0.1 (3.80%)

07:41
09/19/17
09/19
07:41
09/19/17
07:41
Initiation
Rite Aid initiated  »

Rite Aid initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

MDGL

Madrigal Pharmaceuticals

$19.80

0.99 (5.26%)

07:41
09/19/17
09/19
07:41
09/19/17
07:41
Hot Stocks
Madrigal Pharmaceuticals announces positive outcome from pre-planned DSMB review »

Madrigal Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

MDSO

Medidata

$75.85

-0.01 (-0.01%)

07:40
09/19/17
09/19
07:40
09/19/17
07:40
Initiation
Medidata initiated  »

Medidata initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

ABX

Barrick Gold

$16.92

-0.38 (-2.20%)

07:40
09/19/17
09/19
07:40
09/19/17
07:40
Conference/Events
Barrick Gold management to meet with Deutsche Bank »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 26

    Oct

07:40
09/19/17
09/19
07:40
09/19/17
07:40
General news
Treasury Market Outlook: yields are a little lower »

Treasury Market Outlook:…

SFTBF

SoftBank

$78.30

0.3501 (0.45%)

07:39
09/19/17
09/19
07:39
09/19/17
07:39
Periodicals
SoftBank Ventures Korea looks to invest in promising start-ups, CNBC says »

SoftBank Ventures Korea,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCK

McKesson

$148.42

-1.46 (-0.97%)

07:38
09/19/17
09/19
07:38
09/19/17
07:38
Initiation
McKesson initiated  »

McKesson initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 27

    Sep

SUPN

Supernus

$49.65

0.6 (1.22%)

07:37
09/19/17
09/19
07:37
09/19/17
07:37
Downgrade
Supernus rating change  »

Supernus downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.